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Background
Since recent observations demonstrated that extended
resistance to all the three main antiretroviral classes
(NRTI, NNRTI, PI) is a marker of disease progression
and death, the aim of the present analysis is to evaluate
if this situations persists in recent years when several
new potent drugs entered in the current clinical use.
Methods
Patients undergoing genotypic resistance test after treat-
ment failure between 1999-2008 were included. The risk
of progression was calculated with survival analysis
separately for patients who failed between 1999-2003
and 2004-2008. Class resistance for the three historical
drug classes was assessed, using Rega interpretation sys-
tem (v. 8.0.1), when no fully active drug in each class
was detected. Tipranavir, darunavir and etravirine were
not included in the historical drugs classes. The follow-
up was carried out up to December 2009: new AIDS
event/death were considered study endpoint.
Results
Overall, 1522 patients were included, of whom 782 in
the 1999-2003 and 740 in the 2004-2008 group. During
follow-up, 171 and 59 new AIDS/death events were
observed in the two groups, respectively. At survival
analysis, the proportion of patients who achieved the
study endpoint after 5 year of observation was 24% in
the 1999-2003 and 11% in the 2004-2008 group. In the
1999-2003 group, a higher risk of progression in
patients with no active drug in all the three historical
classes was found (41% vs. 19% in patients with ≥1
active class, p=0.03 at adjusted Cox model). In the
2003-2008 group, the risk of progression was lower in
patients with 3-class resistance (25%) while less risk
reduction was found in patients with ≥1 active class
(14%). Indeed, in the 2003-2008 group, 67% of patients
with 3-class resistance were treated with ≥1 drug among
tipranavir, enfuvirtide, darunavir, raltegravir, maraviroc
and etravirine, compared with 45% of patients with 2-
class and 6% of ≤1-class resistance. The most widely
used drug were darunavir (58% of 3-class resistant
patients), tipranavir (55%) and enfuvirtide (45%).
Conclusions
The availability for current use of new drugs, in new
classes and those belonging to old classes but with differ-
ent resistance patterns, may explain the improved survi-
val of the more virologically impaired HIV patients.
However, the improvement in survival does not still
appear so crucial, particularly in patients with active
drugs where a 14% progression at 5 years is still observed.
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